Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

Cytokinetics Inc., solvency ratios (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Debt Ratios
Debt to equity 1.77 1.68 0.59 0.57 8.44 2.02 1.20 0.90 12.63 1.64 0.80 0.43 0.32
Debt to equity (including operating lease liability) 2.91 2.77 1.11 1.05 14.98 3.37 1.23 0.93 15.53 1.64 0.80 0.43 0.32
Debt to capital 3.58 2.20 1.60 1.22 1.03 0.64 0.63 0.37 0.36 0.89 0.67 0.54 0.47 2.44 1.54 1.09 1.80 1.12 0.93 0.62 0.45 0.30 0.24
Debt to capital (including operating lease liability) 2.42 1.80 1.44 1.17 1.02 0.74 0.73 0.53 0.51 0.94 0.77 0.55 0.48 2.30 1.50 1.09 1.61 1.10 0.94 0.62 0.45 0.30 0.24
Debt to assets 0.82 0.78 0.69 0.60 0.57 0.26 0.23 0.17 0.17 0.25 0.24 0.25 0.28 0.57 0.51 0.45 0.24 0.22 0.21 0.20 0.18 0.13 0.11
Debt to assets (including operating lease liability) 1.01 0.96 0.84 0.74 0.69 0.42 0.38 0.32 0.32 0.44 0.40 0.26 0.29 0.59 0.54 0.47 0.28 0.27 0.26 0.20 0.18 0.13 0.11
Financial leverage 6.93 7.36 3.45 3.32 34.22 8.51 4.71 3.17 58.90 8.14 4.42 3.29 2.81
Coverage Ratios
Interest coverage -17.68 -18.36 -17.23 -19.03 -16.02 -14.50 -15.95 -12.10 -13.08 -8.70 -7.50 -6.97 -6.77 -10.66 -12.82 -17.37 -22.22 -22.99 -24.68 -26.99

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Solvency ratio Description The company
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Cytokinetics Inc. debt to capital ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Debt to capital (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. Cytokinetics Inc. debt to capital ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Cytokinetics Inc. debt to assets ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Debt to assets (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. Cytokinetics Inc. debt to assets ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. Cytokinetics Inc. interest coverage ratio deteriorated from Q1 2023 to Q2 2023 but then improved from Q2 2023 to Q3 2023 not reaching Q1 2023 level.

Debt to Equity

Cytokinetics Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Current portion of long-term debt 16,875 11,250 5,625 6,212 2,607 3,778 1,703
Term loan, net, excluding current portion 60,885 62,492 64,110 63,810 63,544 62,344 61,165 47,367 30,203 35,538 40,874 46,209 45,920 45,631 45,340 45,052 44,762 44,473 36,382 39,806 38,127 30,662 31,954
Convertible notes, net 548,134 547,288 546,513 545,808 544,986 134,674 134,511 95,471 93,885 92,348 90,889 89,504 88,102 86,743 85,455 84,205
Total debt 609,019 609,780 610,623 609,618 608,530 197,018 195,676 142,838 140,963 139,136 137,388 135,713 134,022 132,374 130,795 129,257 44,762 44,473 42,594 42,413 41,905 32,365 31,954
 
Stockholders’ equity (deficit) (438,801) (333,115) (229,020) (107,900) (15,977) 111,414 116,261 243,863 249,020 16,489 67,846 113,383 149,605 (78,080) (45,711) (10,937) (19,869) (4,896) 3,372 25,934 52,069 75,170 99,599
Solvency Ratio
Debt to equity1 1.77 1.68 0.59 0.57 8.44 2.02 1.20 0.90 12.63 1.64 0.80 0.43 0.32
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc. 5.02 4.74 4.68 3.67 4.35 4.98 4.51 4.98 5.96 6.53 6.24 6.58 5.70 5.94
Amgen Inc. 7.90 9.08 11.52 10.64 10.60 15.10 40.23 4.97 4.57 3.98 3.50 3.51 3.13 3.21 3.36 3.09 2.73 2.84 3.05
Bristol-Myers Squibb Co. 1.30 1.18 1.19 1.27 1.20 1.29 1.42 1.24 1.20 1.23 1.23 1.34 0.90 0.95 0.94 0.91 1.41 1.56 0.40
Danaher Corp. 0.42 0.38 0.39 0.39 0.41 0.43 0.47 0.49 0.54 0.48 0.50 0.53 0.57 0.62 0.84 0.72 0.54 0.32 0.30
Eli Lilly & Co. 1.80 1.70 1.69 1.52 1.58 1.97 1.77 1.88 2.20 2.56 2.35 2.94 3.51 3.99 5.60 5.88 4.50 5.68 6.44
Gilead Sciences Inc. 1.12 1.19 1.20 1.19 1.20 1.30 1.32 1.27 1.29 1.53 1.59 1.73 1.68 1.34 1.09 1.09 1.19 1.15 1.21
Johnson & Johnson 0.42 0.61 0.75 0.52 0.43 0.43 0.44 0.46 0.48 0.48 0.51 0.56 0.59 0.48 0.45 0.47 0.50 0.48 0.50
Merck & Co. Inc. 0.85 0.95 0.66 0.67 0.68 0.73 0.78 0.87 0.74 0.80 1.16 1.26 0.98 1.12 1.07 1.02 0.97 0.96 0.94
Moderna Inc. 0.04 0.05 0.04 0.05 0.05 0.04 0.04 0.04 0.02 0.05 0.04 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.03
Pfizer Inc. 0.66 0.66 0.36 0.37 0.40 0.46 0.44 0.50 0.53 0.56 0.58 0.63 0.97 0.99 0.80 0.83 0.81 0.78 0.77
Regeneron Pharmaceuticals Inc. 0.11 0.11 0.11 0.12 0.13 0.13 0.14 0.14 0.16 0.18 0.23 0.24 0.27 0.24 0.06 0.06 0.07 0.07 0.08
Thermo Fisher Scientific Inc. 0.78 0.78 0.83 0.78 0.67 0.72 0.81 0.85 0.56 0.51 0.53 0.63 0.66 0.71 0.70 0.60 0.58 0.66 0.66

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= 609,019 ÷ -438,801 =

2 Click competitor name to see calculations.


Debt to Equity (including Operating Lease Liability)

Cytokinetics Inc., debt to equity (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Current portion of long-term debt 16,875 11,250 5,625 6,212 2,607 3,778 1,703
Term loan, net, excluding current portion 60,885 62,492 64,110 63,810 63,544 62,344 61,165 47,367 30,203 35,538 40,874 46,209 45,920 45,631 45,340 45,052 44,762 44,473 36,382 39,806 38,127 30,662 31,954
Convertible notes, net 548,134 547,288 546,513 545,808 544,986 134,674 134,511 95,471 93,885 92,348 90,889 89,504 88,102 86,743 85,455 84,205
Total debt 609,019 609,780 610,623 609,618 608,530 197,018 195,676 142,838 140,963 139,136 137,388 135,713 134,022 132,374 130,795 129,257 44,762 44,473 42,594 42,413 41,905 32,365 31,954
Short-term operating lease liabilities 17,236 15,701 14,263 12,829 16,056 14,303 14,490 14,863 13,586 12,190 5,295 2,785 3,943 5,075 5,030 4,616 4,577 4,538 4,499
Long-term operating lease liabilities 122,216 123,829 125,341 126,895 114,405 112,732 112,023 112,229 106,313 95,713 85,633 440 517 591 1,774 2,195 3,257 4,294 5,272
Total debt (including operating lease liability) 748,471 749,310 750,227 749,342 738,991 324,053 322,189 269,930 260,862 247,039 228,316 138,938 138,482 138,040 137,599 136,068 52,596 53,305 52,365 42,413 41,905 32,365 31,954
 
Stockholders’ equity (deficit) (438,801) (333,115) (229,020) (107,900) (15,977) 111,414 116,261 243,863 249,020 16,489 67,846 113,383 149,605 (78,080) (45,711) (10,937) (19,869) (4,896) 3,372 25,934 52,069 75,170 99,599
Solvency Ratio
Debt to equity (including operating lease liability)1 2.91 2.77 1.11 1.05 14.98 3.37 1.23 0.93 15.53 1.64 0.80 0.43 0.32
Benchmarks
Debt to Equity (including Operating Lease Liability), Competitors2
Moderna Inc. 0.09 0.06 0.05 0.05 0.06 0.04 0.04 0.05 0.03 0.06 0.06 0.08 0.08 0.06 0.09 0.11 0.04 0.03 0.03

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Stockholders’ equity (deficit)
= 748,471 ÷ -438,801 =

2 Click competitor name to see calculations.


Debt to Capital

Cytokinetics Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Current portion of long-term debt 16,875 11,250 5,625 6,212 2,607 3,778 1,703
Term loan, net, excluding current portion 60,885 62,492 64,110 63,810 63,544 62,344 61,165 47,367 30,203 35,538 40,874 46,209 45,920 45,631 45,340 45,052 44,762 44,473 36,382 39,806 38,127 30,662 31,954
Convertible notes, net 548,134 547,288 546,513 545,808 544,986 134,674 134,511 95,471 93,885 92,348 90,889 89,504 88,102 86,743 85,455 84,205
Total debt 609,019 609,780 610,623 609,618 608,530 197,018 195,676 142,838 140,963 139,136 137,388 135,713 134,022 132,374 130,795 129,257 44,762 44,473 42,594 42,413 41,905 32,365 31,954
Stockholders’ equity (deficit) (438,801) (333,115) (229,020) (107,900) (15,977) 111,414 116,261 243,863 249,020 16,489 67,846 113,383 149,605 (78,080) (45,711) (10,937) (19,869) (4,896) 3,372 25,934 52,069 75,170 99,599
Total capital 170,218 276,665 381,603 501,718 592,553 308,432 311,937 386,701 389,983 155,625 205,234 249,096 283,627 54,294 85,084 118,320 24,893 39,577 45,966 68,347 93,974 107,535 131,553
Solvency Ratio
Debt to capital1 3.58 2.20 1.60 1.22 1.03 0.64 0.63 0.37 0.36 0.89 0.67 0.54 0.47 2.44 1.54 1.09 1.80 1.12 0.93 0.62 0.45 0.30 0.24
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc. 0.83 0.83 0.82 0.79 0.81 0.83 0.82 0.83 0.86 0.87 0.86 0.87 0.85 0.86 1.12 1.14 1.27 1.30 1.27
Amgen Inc. 0.89 0.90 0.92 0.91 0.91 0.94 0.98 0.83 0.82 0.80 0.78 0.78 0.76 0.76 0.77 0.76 0.73 0.74 0.75
Bristol-Myers Squibb Co. 0.56 0.54 0.54 0.56 0.54 0.56 0.59 0.55 0.55 0.55 0.55 0.57 0.47 0.49 0.48 0.48 0.59 0.61 0.28
Danaher Corp. 0.30 0.28 0.28 0.28 0.29 0.30 0.32 0.33 0.35 0.32 0.33 0.35 0.37 0.38 0.46 0.42 0.35 0.24 0.23
Eli Lilly & Co. 0.64 0.63 0.63 0.60 0.61 0.66 0.64 0.65 0.69 0.72 0.70 0.75 0.78 0.80 0.85 0.85 0.82 0.85 0.87
Gilead Sciences Inc. 0.53 0.54 0.55 0.54 0.54 0.56 0.57 0.56 0.56 0.60 0.61 0.63 0.63 0.57 0.52 0.52 0.54 0.54 0.55
Johnson & Johnson 0.30 0.38 0.43 0.34 0.30 0.30 0.31 0.31 0.33 0.32 0.34 0.36 0.37 0.33 0.31 0.32 0.33 0.33 0.33
Merck & Co. Inc. 0.46 0.49 0.40 0.40 0.41 0.42 0.44 0.46 0.42 0.44 0.54 0.56 0.50 0.53 0.52 0.50 0.49 0.49 0.48
Moderna Inc. 0.04 0.05 0.04 0.05 0.05 0.03 0.04 0.04 0.02 0.05 0.03 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.03
Pfizer Inc. 0.40 0.40 0.26 0.27 0.28 0.32 0.31 0.33 0.35 0.36 0.37 0.39 0.49 0.50 0.45 0.45 0.45 0.44 0.43
Regeneron Pharmaceuticals Inc. 0.10 0.10 0.10 0.11 0.11 0.12 0.12 0.13 0.14 0.15 0.18 0.20 0.21 0.20 0.06 0.06 0.06 0.07 0.07
Thermo Fisher Scientific Inc. 0.44 0.44 0.45 0.44 0.40 0.42 0.45 0.46 0.36 0.34 0.35 0.39 0.40 0.42 0.41 0.37 0.37 0.40 0.40

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= 609,019 ÷ 170,218 = 3.58

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Cytokinetics Inc. debt to capital ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Debt to Capital (including Operating Lease Liability)

Cytokinetics Inc., debt to capital (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Current portion of long-term debt 16,875 11,250 5,625 6,212 2,607 3,778 1,703
Term loan, net, excluding current portion 60,885 62,492 64,110 63,810 63,544 62,344 61,165 47,367 30,203 35,538 40,874 46,209 45,920 45,631 45,340 45,052 44,762 44,473 36,382 39,806 38,127 30,662 31,954
Convertible notes, net 548,134 547,288 546,513 545,808 544,986 134,674 134,511 95,471 93,885 92,348 90,889 89,504 88,102 86,743 85,455 84,205
Total debt 609,019 609,780 610,623 609,618 608,530 197,018 195,676 142,838 140,963 139,136 137,388 135,713 134,022 132,374 130,795 129,257 44,762 44,473 42,594 42,413 41,905 32,365 31,954
Short-term operating lease liabilities 17,236 15,701 14,263 12,829 16,056 14,303 14,490 14,863 13,586 12,190 5,295 2,785 3,943 5,075 5,030 4,616 4,577 4,538 4,499
Long-term operating lease liabilities 122,216 123,829 125,341 126,895 114,405 112,732 112,023 112,229 106,313 95,713 85,633 440 517 591 1,774 2,195 3,257 4,294 5,272
Total debt (including operating lease liability) 748,471 749,310 750,227 749,342 738,991 324,053 322,189 269,930 260,862 247,039 228,316 138,938 138,482 138,040 137,599 136,068 52,596 53,305 52,365 42,413 41,905 32,365 31,954
Stockholders’ equity (deficit) (438,801) (333,115) (229,020) (107,900) (15,977) 111,414 116,261 243,863 249,020 16,489 67,846 113,383 149,605 (78,080) (45,711) (10,937) (19,869) (4,896) 3,372 25,934 52,069 75,170 99,599
Total capital (including operating lease liability) 309,670 416,195 521,207 641,442 723,014 435,467 438,450 513,793 509,882 263,528 296,162 252,321 288,087 59,960 91,888 125,131 32,727 48,409 55,737 68,347 93,974 107,535 131,553
Solvency Ratio
Debt to capital (including operating lease liability)1 2.42 1.80 1.44 1.17 1.02 0.74 0.73 0.53 0.51 0.94 0.77 0.55 0.48 2.30 1.50 1.09 1.61 1.10 0.94 0.62 0.45 0.30 0.24
Benchmarks
Debt to Capital (including Operating Lease Liability), Competitors2
Moderna Inc. 0.09 0.05 0.05 0.05 0.05 0.04 0.04 0.05 0.03 0.06 0.06 0.07 0.07 0.05 0.08 0.10 0.04 0.03 0.03

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 748,471 ÷ 309,670 = 2.42

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. Cytokinetics Inc. debt to capital ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Debt to Assets

Cytokinetics Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Current portion of long-term debt 16,875 11,250 5,625 6,212 2,607 3,778 1,703
Term loan, net, excluding current portion 60,885 62,492 64,110 63,810 63,544 62,344 61,165 47,367 30,203 35,538 40,874 46,209 45,920 45,631 45,340 45,052 44,762 44,473 36,382 39,806 38,127 30,662 31,954
Convertible notes, net 548,134 547,288 546,513 545,808 544,986 134,674 134,511 95,471 93,885 92,348 90,889 89,504 88,102 86,743 85,455 84,205
Total debt 609,019 609,780 610,623 609,618 608,530 197,018 195,676 142,838 140,963 139,136 137,388 135,713 134,022 132,374 130,795 129,257 44,762 44,473 42,594 42,413 41,905 32,365 31,954
 
Total assets 740,614 779,899 889,815 1,014,775 1,075,961 771,717 856,253 841,319 827,539 564,302 577,062 533,803 474,112 232,495 256,582 289,814 187,393 198,218 198,611 211,178 230,279 247,239 279,926
Solvency Ratio
Debt to assets1 0.82 0.78 0.69 0.60 0.57 0.26 0.23 0.17 0.17 0.25 0.24 0.25 0.28 0.57 0.51 0.45 0.24 0.22 0.21 0.20 0.18 0.13 0.11
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc. 0.45 0.45 0.46 0.46 0.49 0.51 0.51 0.52 0.54 0.56 0.57 0.57 0.58 0.58 0.74 0.75 0.65 0.65 0.65
Amgen Inc. 0.67 0.68 0.69 0.60 0.61 0.62 0.62 0.54 0.58 0.55 0.52 0.52 0.53 0.53 0.52 0.50 0.50 0.52 0.52
Bristol-Myers Squibb Co. 0.41 0.40 0.40 0.41 0.40 0.42 0.44 0.41 0.40 0.41 0.41 0.43 0.36 0.36 0.36 0.36 0.43 0.45 0.17
Danaher Corp. 0.25 0.23 0.23 0.23 0.24 0.25 0.26 0.27 0.29 0.26 0.27 0.28 0.30 0.31 0.38 0.35 0.29 0.19 0.18
Eli Lilly & Co. 0.35 0.34 0.36 0.33 0.33 0.36 0.35 0.35 0.35 0.35 0.35 0.36 0.39 0.39 0.42 0.39 0.40 0.41 0.42
Gilead Sciences Inc. 0.40 0.40 0.41 0.40 0.40 0.42 0.42 0.39 0.41 0.44 0.45 0.46 0.48 0.43 0.40 0.40 0.42 0.41 0.42
Johnson & Johnson 0.18 0.24 0.27 0.21 0.18 0.18 0.19 0.19 0.19 0.19 0.19 0.20 0.22 0.19 0.18 0.18 0.19 0.19 0.20
Merck & Co. Inc. 0.33 0.35 0.29 0.28 0.28 0.30 0.30 0.31 0.28 0.29 0.34 0.35 0.32 0.34 0.33 0.31 0.31 0.32 0.31
Moderna Inc. 0.03 0.04 0.03 0.04 0.04 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.03 0.02
Pfizer Inc. 0.30 0.30 0.18 0.18 0.19 0.21 0.20 0.21 0.22 0.23 0.25 0.26 0.35 0.36 0.31 0.31 0.31 0.30 0.29
Regeneron Pharmaceuticals Inc. 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.13 0.15 0.16 0.17 0.15 0.05 0.05 0.05 0.05 0.06
Thermo Fisher Scientific Inc. 0.36 0.36 0.37 0.35 0.32 0.33 0.36 0.37 0.29 0.28 0.28 0.31 0.33 0.35 0.34 0.30 0.30 0.33 0.33

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= 609,019 ÷ 740,614 = 0.82

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Cytokinetics Inc. debt to assets ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Debt to Assets (including Operating Lease Liability)

Cytokinetics Inc., debt to assets (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Current portion of long-term debt 16,875 11,250 5,625 6,212 2,607 3,778 1,703
Term loan, net, excluding current portion 60,885 62,492 64,110 63,810 63,544 62,344 61,165 47,367 30,203 35,538 40,874 46,209 45,920 45,631 45,340 45,052 44,762 44,473 36,382 39,806 38,127 30,662 31,954
Convertible notes, net 548,134 547,288 546,513 545,808 544,986 134,674 134,511 95,471 93,885 92,348 90,889 89,504 88,102 86,743 85,455 84,205
Total debt 609,019 609,780 610,623 609,618 608,530 197,018 195,676 142,838 140,963 139,136 137,388 135,713 134,022 132,374 130,795 129,257 44,762 44,473 42,594 42,413 41,905 32,365 31,954
Short-term operating lease liabilities 17,236 15,701 14,263 12,829 16,056 14,303 14,490 14,863 13,586 12,190 5,295 2,785 3,943 5,075 5,030 4,616 4,577 4,538 4,499
Long-term operating lease liabilities 122,216 123,829 125,341 126,895 114,405 112,732 112,023 112,229 106,313 95,713 85,633 440 517 591 1,774 2,195 3,257 4,294 5,272
Total debt (including operating lease liability) 748,471 749,310 750,227 749,342 738,991 324,053 322,189 269,930 260,862 247,039 228,316 138,938 138,482 138,040 137,599 136,068 52,596 53,305 52,365 42,413 41,905 32,365 31,954
 
Total assets 740,614 779,899 889,815 1,014,775 1,075,961 771,717 856,253 841,319 827,539 564,302 577,062 533,803 474,112 232,495 256,582 289,814 187,393 198,218 198,611 211,178 230,279 247,239 279,926
Solvency Ratio
Debt to assets (including operating lease liability)1 1.01 0.96 0.84 0.74 0.69 0.42 0.38 0.32 0.32 0.44 0.40 0.26 0.29 0.59 0.54 0.47 0.28 0.27 0.26 0.20 0.18 0.13 0.11
Benchmarks
Debt to Assets (including Operating Lease Liability), Competitors2
Moderna Inc. 0.07 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.02 0.03 0.02 0.03 0.04 0.05 0.07 0.08 0.03 0.03 0.02

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 748,471 ÷ 740,614 = 1.01

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. Cytokinetics Inc. debt to assets ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Financial Leverage

Cytokinetics Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Total assets 740,614 779,899 889,815 1,014,775 1,075,961 771,717 856,253 841,319 827,539 564,302 577,062 533,803 474,112 232,495 256,582 289,814 187,393 198,218 198,611 211,178 230,279 247,239 279,926
Stockholders’ equity (deficit) (438,801) (333,115) (229,020) (107,900) (15,977) 111,414 116,261 243,863 249,020 16,489 67,846 113,383 149,605 (78,080) (45,711) (10,937) (19,869) (4,896) 3,372 25,934 52,069 75,170 99,599
Solvency Ratio
Financial leverage1 6.93 7.36 3.45 3.32 34.22 8.51 4.71 3.17 58.90 8.14 4.42 3.29 2.81
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc. 11.26 10.52 10.14 8.04 8.84 9.77 8.80 9.51 10.99 11.77 10.98 11.51 9.80 10.17
Amgen Inc. 11.83 13.31 16.59 17.79 17.44 24.51 64.62 9.13 7.91 7.25 6.70 6.69 5.90 6.10 6.50 6.17 5.45 5.50 5.91
Bristol-Myers Squibb Co. 3.15 2.92 2.96 3.12 3.01 3.08 3.26 3.04 2.98 3.01 2.99 3.13 2.50 2.61 2.59 2.52 3.25 3.44 2.29
Danaher Corp. 1.67 1.64 1.65 1.68 1.72 1.76 1.80 1.84 1.90 1.82 1.87 1.92 1.92 1.97 2.22 2.05 1.89 1.66 1.64
Eli Lilly & Co. 5.16 4.95 4.75 4.65 4.71 5.51 5.03 5.44 6.21 7.42 6.79 8.27 9.10 10.25 13.35 15.07 11.20 13.91 15.32
Gilead Sciences Inc. 2.80 2.95 2.95 2.97 2.97 3.11 3.17 3.23 3.13 3.45 3.56 3.76 3.49 3.10 2.71 2.74 2.87 2.79 2.86
Johnson & Johnson 2.33 2.55 2.77 2.44 2.35 2.33 2.39 2.46 2.55 2.54 2.62 2.76 2.65 2.51 2.53 2.65 2.67 2.55 2.54
Merck & Co. Inc. 2.59 2.70 2.30 2.37 2.41 2.48 2.61 2.77 2.61 2.72 3.37 3.62 3.08 3.28 3.24 3.26 3.10 3.04 2.99
Moderna Inc. 1.45 1.29 1.28 1.35 1.45 1.45 1.62 1.74 2.07 2.41 3.31 2.86 1.69 1.18 1.26 1.35 1.27 1.26 1.25
Pfizer Inc. 2.22 2.22 1.94 2.06 2.10 2.24 2.23 2.35 2.37 2.43 2.31 2.44 2.74 2.77 2.56 2.65 2.62 2.62 2.64
Regeneron Pharmaceuticals Inc. 1.29 1.28 1.28 1.29 1.29 1.32 1.32 1.36 1.37 1.42 1.48 1.56 1.59 1.59 1.30 1.34 1.33 1.35 1.36
Thermo Fisher Scientific Inc. 2.14 2.15 2.24 2.21 2.08 2.14 2.26 2.33 1.90 1.84 1.88 2.00 2.01 2.06 2.05 1.97 1.93 2.02 2.01

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= 740,614 ÷ -438,801 =

2 Click competitor name to see calculations.


Interest Coverage

Cytokinetics Inc., interest coverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Net loss (129,422) (128,637) (131,289) (137,380) (142,310) (19,820) (89,445) (30,570) (76,086) (61,554) (47,104) (43,930) (3,175) (40,780) (39,405) (30,640) (29,573) (32,113) (29,366) (26,468) (22,017) (27,523) (30,281)
Add: Income tax expense
Add: Interest expense 7,136 7,045 6,961 7,057 6,804 2,807 2,746 4,218 4,161 4,073 3,988 4,018 3,976 3,892 4,077 2,731 1,345 1,377 1,170 1,169 867 898 863
Earnings before interest and tax (EBIT) (122,286) (121,592) (124,328) (130,323) (135,506) (17,013) (86,699) (26,352) (71,925) (57,481) (43,116) (39,912) 801 (36,888) (35,328) (27,909) (28,228) (30,736) (28,196) (25,299) (21,150) (26,625) (29,418)
Solvency Ratio
Interest coverage1 -17.68 -18.36 -17.23 -19.03 -16.02 -14.50 -15.95 -12.10 -13.08 -8.70 -7.50 -6.97 -6.77 -10.66 -12.82 -17.37 -22.22 -22.99 -24.68 -26.99
Benchmarks
Interest Coverage, Competitors2
Amgen Inc. 4.54 5.43 6.51 6.22 6.83 6.97 6.40 6.60 6.46 6.48 7.64 7.44 7.62 7.62 7.85 8.09
Danaher Corp. 23.66 29.65 35.60 40.30 41.32 35.26 33.54 32.92 28.74 25.87 21.54 17.35 16.90 20.00 25.33 31.44
Gilead Sciences Inc. 8.88 9.03 8.84 7.22 5.80 6.73 6.97 9.27 10.06 7.61 2.93 2.70 2.83 0.41 5.90 6.19
Johnson & Johnson 19.09 23.89 31.49 79.71 141.63 160.27 164.15 125.46 94.27 87.06 73.87 83.07 96.82 81.36 81.56 55.49
Regeneron Pharmaceuticals Inc. 61.70 69.61 73.97 82.80 108.62 116.35 163.24 163.75 139.74 104.12 68.20 67.97 72.22 108.12 90.22 81.43
Thermo Fisher Scientific Inc. 5.98 6.64 8.28 11.56 13.59 15.70 16.73 17.49 19.94 19.52 17.58 14.07 10.78 7.93 7.66 7.02

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Interest coverage = (EBITQ3 2023 + EBITQ2 2023 + EBITQ1 2023 + EBITQ4 2022) ÷ (Interest expenseQ3 2023 + Interest expenseQ2 2023 + Interest expenseQ1 2023 + Interest expenseQ4 2022)
= (-122,286 + -121,592 + -124,328 + -130,323) ÷ (7,136 + 7,045 + 6,961 + 7,057) = -17.68

2 Click competitor name to see calculations.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. Cytokinetics Inc. interest coverage ratio deteriorated from Q1 2023 to Q2 2023 but then improved from Q2 2023 to Q3 2023 not reaching Q1 2023 level.